Laetitia Comps-Agrar
Principal Scientist (Technology), Biochemical and Cellular Pharmacology
"I am fortunate to work in such a highly collaborative environment with top-tiered scientists, who aim at conducting high quality science and translate it into transformative medicines for patients."
I obtained a PhD in Molecular Pharmacology at the University of Montpellier, France, where I studied the pharmacology of G-protein coupled receptors and delineated how their oligomerization influences their physiological function. I joined Genentech as a post-doctoral fellow in 2011. During that time, I was involved in three research projects that translated into molecules that made it to the clinic. This was an exciting time that contributed to my decision to stay with the company as a scientist and lead my own lab. I could not think of a better place to do science at its highest level and translate these findings into therapeutics that could benefit patients.
Currently, my group supports therapeutic antibodies efforts within multi-disciplinary project teams in the therapeutic areas of ocular, cancer-immunology and oncology.
Featured Publication
Massive antibody discovery used to probe structure-function relationships of the essential outer membrane protein LptD.
Elife 8. pii: e46258. (2019).
Unliganded fibroblast growth factor receptor 1 forms density-independent dimers.
J Biol Chem. 290(40):24166-77. (2015).
The immunoreceptor TIGIT regulates anti-tumor and anti-viral CD8+ T cell effector function.
Cancer Cell 26(6):923-37. (2015).